JAGX Company Profile and Key Details

Q: Who are the executives of JAGX?

Mr. David SesinChief Manufacturing OfficerDr. Michael K. Guy D.V.M., M.S., Ph.D.Vice President of Preclinical & Nonclinical StudiesMs. Carol R. LizakChief Financial OfficerMr. Jonathan S. Wolin C.P.A., J.D., M.B.A.Chief of Staff, Chief Compliance Officer & Gen. CounselMs. Lisa A. ConteFounder, Chief Executive Officer, Pres & DirectorDr. Pravin R. Chaturvedi Ph.D.Chief Scientific Officer & Chair of Scientific Advisory BoardMr. Jonathan S. Wolin CPA, J.D., M.B.A.Chief of Staff, Chief Compliance Officer & Gen. CounselMr. Ian H. Wendt M.B.A.Chief Commercial OfficerDr. Steven R. King Ph.D.Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.Ms. Carol R. Lizak M.B.A.Chief Financial OfficerMr. Peter HodgeSenior Director of Investor Relations, Bus. Devel. & Special EventsDr. Karen J. Brunke Ph.D.Executive Vice President of Corporation & Bus. Devel.

NASDAQ : JAGX

Jaguar Health

$0.40

-0.00599999-1.48%

At Close 4:00 PM

69.68

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Jaguar Health, Inc. (JAGX) stock declined over -1.48%, trading at $0.40 on NASDAQ, down from the previous close of $0.41. The stock opened at $0.39, fluctuating between $0.37 and $0.41 in the recent session.

Stock Snapshot

0.406

Prev. Close

869.75K

Market Cap

0.3701

Day Low

-0.16

P/E Ratio

-2.58

EPS (TTM)

-0.45

Cash Flow per Share

0.39

Open

2.17M

Number of Shares

0.4098

Day High

70.04%

Free Float in %

0.07

Book Value

187.04K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	0.39	0.41	0.37	0.40	197.15K
Apr 01, 2026	0.37	0.48	0.37	0.41	851.35K
Mar 31, 2026	0.35	0.37	0.33	0.37	156.12K
Mar 30, 2026	0.35	0.35	0.31	0.33	279.23K
Mar 27, 2026	0.39	0.39	0.34	0.34	310.44K
Mar 25, 2026	0.40	0.42	0.39	0.42	242.63K
Mar 24, 2026	0.41	0.41	0.38	0.40	144.42K
Mar 23, 2026	0.42	0.42	0.38	0.40	329.87K
Mar 20, 2026	0.40	0.43	0.40	0.42	331.52K
Mar 19, 2026	0.43	0.43	0.40	0.42	421.37K
Mar 18, 2026	0.48	0.48	0.43	0.44	679.44K
Mar 17, 2026	0.51	0.54	0.46	0.48	429.35K
Mar 16, 2026	0.53	0.53	0.49	0.50	257.59K
Mar 13, 2026	0.55	0.56	0.49	0.50	447.11K
Mar 12, 2026	0.54	0.56	0.51	0.55	367.72K
Mar 11, 2026	0.47	0.60	0.46	0.56	658.77K
Mar 10, 2026	0.49	0.50	0.47	0.47	618.58K
Mar 09, 2026	0.59	0.60	0.48	0.49	1.21M
Mar 06, 2026	0.60	0.62	0.59	0.59	305.18K
Mar 03, 2026	0.81	0.83	0.59	0.62	1.38M

Contact Details

San Francisco, CA 94104

United States

https://jaguar.health 415 371 8300

About Company

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer for multiple possible follow-on indications, including cancer therapy-related diarrhea; orphan-drug indications for symptomatic relief of diarrhea in infants and children with congenital diarrheal disorders and for adult and pediatric patients for short bowel syndrome with intestinal failure with; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops lechlemer, a second-generation anti-secretory agent for cholera; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Jaguar Health, Inc. was founded in 2013 and is headquartered in San Francisco, California.

Stock Peers

REGN

-15.4-1.98%

Regeneron Pharmaceuticals, Inc.$761.85 ARGX

3.3+0.44%

argenx SE$746.42 UTHR

-5.46-0.96%

United Therapeutics Corporation$564.81 MDGL

17.05+3.22%

Madrigal Pharmaceuticals, Inc.$546.89 VRTX

-8.55-1.91%

Vertex Pharmaceuticals Incorporated$438.71 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-9.88-3.01%

Alnylam Pharmaceuticals, Inc.$318.85 PRAX

-8.9-2.79%

Praxis Precision Medicines, Inc.$310.38 KRYS

2.04+0.79%

Krystal Biotech, Inc.$260.95 ASND

1.01+0.44%

Ascendis Pharma A/S$229.25

Company Overview

Jaguar Health, Inc. (NASDAQ:JAGX) closed at $0.40 USD, losing -$0.01 (-1.48%) from the previous close of $0.41. The stock is currently mid-range between its 52-week high and low $0.31 and $15.48. With a market capitalization of about $869.75 thousand, Jaguar Health, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.29). Key stats such as the average daily volume over the past year has been around 3.79 million shares, volume is running light vs its 52-week average. Headquartered in San Francisco, CA, Jaguar Health, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Lisa A. Conte, the company employs approximately 49 people and listed since May 12, 2015. Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic, and debilitating diarrhea.

Technical Performance

JAGX has shown mixed momentum, gaining 3.01% over the past week and -58.89% over the past quarter, though year-to-date performance is down -8.18%. Short-term trend indicators are bullishly aligned (SMA20 29.88%, SMA50 0.07%, SMA200 -58.51%). The stock’s 14-day RSI is 58.05 (neutral), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -95.49% below its high and over 52.45% above its low. Average 10-day trading volume of 339.49 thousand shares is below the 3-month average of 3.85 million, indicating normal recent market interest.

Valuation Metrics

Jaguar Health, Inc. trades at a P/E ratio of -0.02, slightly below the S&P 500 average, with a price-to-sales ratio of 0.07 and a price-to-book ratio of 0.11 suggesting the stock is closer to book value. The P/FCF stands at -0.03, also above market averages.

Dividend & Fair Value

Jaguar Health, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.98. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Jaguar Health, Inc. generated EPS of -$33.98 over the past year. Five-year average earnings growth is 69.64%. Wall Street analysts project EPS growth of 87.27% annually over the next five years. Jaguar Health, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 47.42%. The prior quarter beat by 101.97%. Over the last six quarters, Apple has recorded several small beats. These include 236.67% in August 13, 2024.

Shareholding & Insider Activity

Jaguar Health, Inc. has 1.91 million shares outstanding. The public float is 2.12 million shares, elevated short interest at 2.30% of float. This equals 44.02 thousand shares. The short ratio is 0.47 days. Institutional investors hold 0.96% of the float. Insiders own 34.76%. Sagard Capital Partners, L.P. holds 5.52 million shares, BOCHNOWSKI JAMES J has 27.00 thousand shares and Siegel Jonathan B. has 9.00 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Jaguar Health generated $9.76M in revenue, or $0.42 per share. Gross margin was 54.67%, operating margin -347.51%, and net profit margin -423.11%. Returns are negative, with ROA at -81.36% and ROE at -832.49%.
On valuation metrics, Jaguar Health trades at a P/E of -0.02, P/S of 0.07 and P/B of 0.11. Liquidity is tight, with a current ratio of 0.81 and quick ratio of 0.52. Operationally, the company’s inventory turnover is 0.25 and cash conversion cycle is 340.87 days. Debt-to-equity is 5.67, supported by a cash flow-to-debt ratio of -0.82.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Jaguar Health posted revenue of $9.76M, down slightly from $11.96M in the prior quarter. Gross profit was $5.34M (margin 54.67%). Operating income was - $33.92M (margin -347.5%). Net income was- $41.30M (EPS - $1.79).
The company ended the quarter with $6.47M in cash and short-term investments, a total debt of $37.09M, and net debt of $30.63M. Total assets were $50.76M, with equity of $4.90M. Financials further reflected weakness, with operating cash flow of - $33.24M, free cash flow of - $33.24M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Jaguar Health, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -25.0%, with price expected at $0.30 by April 16, 2026, within a range of $0.17 to $0.43 3-Month Outlook: Projected fall of -30.0%, reaching $0.28 by July 01, 2026, with a range of $0.00 to $0.73. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by April 02, 2027, within a range of $0.00 to $174.28.

Key Takeaways

Jaguar Health, Inc. (NASDAQ:JAGX) shares are flat -8.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Jaguar Health, Inc. trading at a premium to the broader market with a P/E of -0.02. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $3.50, suggesting 775.0% upside. Our AI forecast model points to short-term weakness (-25.0% over two weeks), a medium-term fall (-30.0% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Jaguar Health, Inc. (JAGX) stock price?

Jaguar Health, Inc. (NASDAQ: JAGX) stock price is $0.40 in the last trading session. During the trading session, JAGX stock reached the peak price of $0.41 while $0.37 was the lowest point it dropped to. The percentage change in JAGX stock occurred in the recent session was -1.48% while the dollar amount for the price change in JAGX stock was - $0.01.

JAGX's industry and sector of operation?

The NASDAQ listed JAGX is part of Biotechnology industry that operates in the broader Healthcare sector. Jaguar Health, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of JAGX?

Mr. David Sesin
Chief Manufacturing Officer
Dr. Michael K. Guy D.V.M., M.S., Ph.D.
Vice President of Preclinical & Nonclinical Studies
Ms. Carol R. Lizak
Chief Financial Officer
Mr. Jonathan S. Wolin C.P.A., J.D., M.B.A.
Chief of Staff, Chief Compliance Officer & Gen. Counsel
Ms. Lisa A. Conte
Founder, Chief Executive Officer, Pres & Director
Dr. Pravin R. Chaturvedi Ph.D.
Chief Scientific Officer & Chair of Scientific Advisory Board
Mr. Jonathan S. Wolin CPA, J.D., M.B.A.
Chief of Staff, Chief Compliance Officer & Gen. Counsel
Mr. Ian H. Wendt M.B.A.
Chief Commercial Officer
Dr. Steven R. King Ph.D.
Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Sec.
Ms. Carol R. Lizak M.B.A.
Chief Financial Officer
Mr. Peter Hodge
Senior Director of Investor Relations, Bus. Devel. & Special Events
Dr. Karen J. Brunke Ph.D.
Executive Vice President of Corporation & Bus. Devel.

How JAGX did perform over past 52-week?

JAGX's closing price is 27.8% higher than its 52-week low of $0.31 where as its distance from 52-week high of $15.48 is -97.42%.

How many employees does JAGX have?

Number of JAGX employees currently stands at 49.

Link for JAGX official website?

Official Website of JAGX is: https://jaguar.health

How do I contact JAGX?

JAGX could be contacted at phone 415 371 8300 and can also be accessed through its website. JAGX operates from 200 Pine Street, San Francisco, CA 94104, United States.

How many shares of JAGX are traded daily?

JAGX stock volume for the day was 187.04K shares. The average number of JAGX shares traded daily for last 3 months was 3.79M.

What is the market cap of JAGX currently?

The market value of JAGX currently stands at $869.75K with its latest stock price at $0.40 and 2.17M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	49
Beta	0.05
Sales or Revenue	$9.76M
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

JAGX Company Profile and Key Details

Jaguar Health

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Earnings & Analyst Outlook

Technical Performance

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Valuation Metrics

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways